Increasing Engagement With Messages Regarding CRC Screening Among Adults Aged 45-49
NCT ID: NCT05281159
Last Updated: 2023-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20509 participants
INTERVENTIONAL
2022-02-21
2022-11-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Choice on Colorectal Cancer Screening
NCT05275530
Screen to Save: NCI Colorectal Cancer Outreach & Screening Initiative
NCT05064410
Improving Rates of Repeat Colorectal Cancer Screening
NCT01453894
Does Knowing One's Estimated Colorectal Cancer Risk Influence Screening Behavior?
NCT03819920
Assessing Repeat Fit Testing for CRC
NCT03248661
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This current study will be a nested study within a larger investigation to determine the most effective patient outreach approach to increase patients' engagement with messages regarding CRC screening and CRC screening utilization in average-risk individuals ages 45-49 years. Here the investigators are testing which type of SMS messaging is most effective in prompting people to review MyChart message regarding CRC screening and thus increasing CRC screening uptake among individuals 45-49 years old.
There will be three different text messages that have been formulated utilizing behavioral science principles, and then randomize them equally among the eligible population. There will be stratified patient randomization based on arm assignment in our 'CRC45+ Choice' evaluation to prevent cross-study contamination. The arms for this investigation will be 1) Control, 2) Risk Information and 3) Risk Information + Action. In the control (standard care) arm, patients will receive the standard SMS text message. In the Risk Information arm, patients will receive a message indicating their risk for colorectal cancer, on top of the content in the Control arm. Finally, in the Risk Information + Action arm patients will receive risk information and importance of taking quick action, on top of the content in the Control arm. The investigators will also randomly assign patients into receiving our text message on one of ten workdays, stratifying by arm assignment in both the CRC45+ Choice Evaluation and CRC45+ Text Evaluation.
We will send text reminders to patients two weeks after they receive the initial text message. Reminder content will be very similar to the content of initial text message, and differ by arm.
For this investigation the investigators hypothesize:
1. Hyp 1: Patients assigned to the Risk Information + Action Arm (Arm 2) will have a higher click rate than patients assigned to the Control Arm (Arm 0)
2. Hyp 2: Patients assigned to the Risk Information + Action Arm (Arm 2) will have a higher click rate than patients assigned to the Risk Information Arm (Arm 1)
Analysis: The investigators will utilize patient-level ordinary least squares (OLS) estimation, with statistical inferences based on model-robust standard errors. The primary model term will be indicator variables for arm assignment.
The analysis will adjust for sex, race/ethnicity, social vulnerability index (at the ZIP code level), and MyChart logins decile.
Treatment effects will be summarized using rate differences and 95% CI's. Exploratory analyses will investigate heterogenous treatment effects by demographic subgroups by splitting the sample into each demographic subgroup as well as by testing demographics and text message arm interactions. Sensitivity analyses will be performed without covariates, and using logistic regression models in place of linear regression models. Missing covariate values will be handled by including 'unknown' indicators, along with mean imputation for quantitative covariates.
The investigators will additionally explore how click rates within the SMS message vary with the day of the week.
Primary analyses will use intention-to-treat protocol.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Parallel-arm randomized controlled trial,
* Three arms
* Arm 0: Standard of care control (standard text messaging)
* Arm 1: Experimental, "Risk Information" group
* Arm 2: Experimental, "Risk Information + Action" group
* Patient-level randomization stratified by arm assignment in CRC45+ Choice Evaluation. The investigators will also randomly assign patients into receiving the text message on one of ten workdays, stratifying by arm assignment in both the CRC45+ Choice Evaluation and CRC45+ Text Evaluation
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
This group will receive a standard SMS text message indicating that they have a MyChart message from their provider about CRC screening and should follow a link to be screened.
No interventions assigned to this group
"Risk Information"
This group will receive an SMS text message highlighting their risk for CRC.
Risk Information
This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
"Risk Information + Action"
This group will receive an SMS message highlighting their risk for CRC and the importance of taking quick action.
Risk Information + Action
This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Risk Information
This group will receive an SMS text message highlighting their risk for CRC on top of the content in the Control arm.
Risk Information + Action
This group will receive an SMS text message highlighting their risk for CRC and the importance of taking quick action, on top of the content in the Control arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 45-49 (as of 2/1/2022)
* Active primary care provider
* Visit within the last 3 years
Exclusion Criteria
* Documented family history of CRC in EMR
* History (personal or family) of prior adenomatous polyps in the EMR
* History of high-risk cancer syndromes (e.g., Lynch, FAP)
* Prior CRC screening with colonoscopy or FIT
* Inactive MyChart status at enrollment
* No documented SMS-capable phone number
45 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCLA Vatche and Tamar Manoukian Division of Digestive Diseases
UNKNOWN
Carnegie Mellon University
OTHER
University of California, Los Angeles
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel M. Croymans, MD, MBA, MS
Medical Director, DOM Quality
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA Health Department of Medicine, Quality Office
Westwood, Los Angeles, California, United States
UCLA Vatche and Tamar Manoukian Division of Digestive Diseases
Westwood, Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRC45+TEXT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.